Press releases

March 30, 2017

Advanced Accelerator Applications Signs Strategic Supply Agreement with University of Missouri for Lutetium 177

March 23, 2017

Advanced Accelerator Applications Reports 23% Sales Growth for Fiscal 2016; Continued NETSPOT® Launch Success

March 15, 2017

Advanced Accelerator Applications to Announce Full-Year 2016 Financial Results on March 23

March 6, 2017

Advanced Accelerator Applications Announces Presentation of Quality of Life Findings from NETTER-1 Phase III Study at ENETS

March 1, 2017

Advanced Accelerator Applications Announces Addition of NETSPOT® to National Comprehensive Cancer Network® Guidelines for Evaluation of NETs

January 12, 2017

Advanced Accelerator Applications Announces New England Journal of Medicine Publication of Lutathera® NETTER-1 Phase III Results

January 9, 2017

Advanced Accelerator Applications CEO Provides Progress Report on Corporate Developments of 2016; Asserts Confidence in Ability to Address FDA Comments on Lutathera® NDA

January 4, 2017

Advanced Accelerator Applications to Present at 35th Annual J.P. Morgan Healthcare Conference

December 21, 2016

Advanced Accelerator Applications Receives Complete Response Letter from FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors

December 15, 2016

Advanced Accelerator Applications Announces European Commission Approval of SomaKit TOC™

December 8, 2016

Advanced Accelerator Applications Announces CMS Pass-Through Reimbursement Code for its First FDA Approved Drug NETSPOT®

November 28, 2016

Advanced Accelerator Applications Reports 15.4% Sales Growth in the Third Quarter of 2016 and Feedback from the FDA for Lutathera®, an Investigational Treatment for Neuroendocrine Tumors

November 23, 2016

Advanced Accelerator Applications to Announce Third Quarter and Nine-Month 2016 Financial Results on November 28

November 2, 2016

Advanced Accelerator Applications Announces Swiss Marketing Authorization for Two PET Diagnostic Products

October 17, 2016

Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC

October 11, 2016

Advanced Accelerator Applications Announces Presentations on Lutathera® NETTER-1 Phase III and NeoBOMB1 at EANM

October 5, 2016

Advanced Accelerator Applications S.A. Announces Pricing of $150 Million Public Offering of American Depositary Shares

October 4, 2016

Advanced Accelerator Applications S.A. Announces Proposed Public Offering of American Depositary Shares

September 20, 2016

Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera®

September 16, 2016

Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection

September 6, 2016

Advanced Accelerator Applications Announces Two Phase II Studies Evaluating 99MTc-rhAnnexin V-128 Imaging in Cardiovascular and Cardio-Oncology Indications at University of Ottawa Heart Institute and Ottawa Hospital

September 1, 2016

Advanced Accelerator Applications Reports 24.4% Sales Growth in the Second Quarter of 2016 – Launches First U.S. Product and Continues Momentum with Pipeline

August 3, 2016

Advanced Accelerator Applications Announces First Administration of NETSPOT™ at Holy Name Medical Center

August 2, 2016

Advanced Accelerator Applications Announces Clinical Trial Agreement with National Cancer Institute for Study of Lutathera in Patients with Inoperable Pheochromocytoma and Paraganglioma